Summer Adjournment

Pauline Latham Excerpts

Tuesday 19th July 2011 Commons Chamber

[Pauline Latham (Mid Derbyshire) (Con)]

I wish to bring to the attention of the House and particularly the Minister the east midlands cancer drugs fund. The original concept of the fund was to help thousands of extra cancer patients receive treatment if their clinicians believed it would help them. The policy was warmly welcomed by cancer patients and their families. I have had two patients come to my surgeries on different occasions trying to access the life-prolonging drugs Avastin and Rituximab.

Since my election, I have discovered enormous anomalies between different parts of the cancer drugs fund. The East Midlands strategic health authority provides Avastin for the first-line treatment of both metastatic colorectal cancer and renal cell carcinoma, but it will not make provision for the use of Avastin as second-line treatment. In fact, it has been rather obstructive in giving us information about what it does. That has turned the life of one of my constituents, who is a cancer patient, into a living nightmare. In order to prolong her life, my constituent, who wishes to remain anonymous, has to date spent more than £50,000 of her own money on funding second-line treatment with Avastin. That included money that she got from taking early retirement. She has also sold many of her possessions, including her car and family heirlooms, to continue her treatment. But now she is running out of things to sell.

The drug costs my constituent £1,600 every three weeks—a sum that most people would find very hard to find—but she is still alive, which she would not be had she not funded it herself. She is living proof of the effectiveness of the drug in second-line treatment. However, if she resided just 12 miles away in Staffordshire, she would fall under the West Midlands SHA, which has confirmed that it provides Avastin—the drug that she so desperately needs to stay alive—for patients on both first and second-line treatments to treat the type of cancer that she is suffering from. However, the East Midlands SHA has not approved any applications for Avastin for second-line treatment of bowel cancer. This lack of consistency across the country is appalling. The Avastin that my constituent has funded herself, when used alongside chemotherapy, has seen her tumour levels drop from 41 to five—so clearly it is working very well. She is naturally infuriated that the east midlands cancer drugs fund is so resistant to funding Avastin for second-line treatment. I cannot understand why it is not looking at the clear medical evidence that she personally presents showing the effectiveness of the drug. She is living evidence that the medicine works, and she needs such help now.

I know of another patient with scleroderma who has been refused Rituximab. Hers is a terminal illness and she is being refused the drug. According to her doctors, she has three years left to live. She was told seven months after she applied that she could not have it, and it takes six months to take effect, so this lady is having enormous difficulty in understanding why she is not allowed it. She has been to London and been told that, yes, people get it there, but she cannot have it in the east midlands. I would therefore like to ask the Minister whether he will see how he can help those two brave individuals, because although I believe in local decision making, the current situation is just not fair, and they are not getting the treatment that they both deserve.